Clinical Trials Logo

Lymphoma, B-cell clinical trials

View clinical trials related to Lymphoma, B-cell.

Filter by:

NCT ID: NCT05016947 Recruiting - B-Cell Lymphoma Clinical Trials

Venetoclax Plus Inotuzumab for B-ALL

Start date: September 24, 2021
Phase: Phase 1
Study type: Interventional

This research study is evaluating the safety and efficacy of administering venetoclax and inotuzumab ozogamicin in combination in patients with acute lymphoblastic leukemia (ALL) The names of the study drugs involved in this study are: - Venetoclax - Inotuzumab ozogamicin - Dexamethasone

NCT ID: NCT05014100 Not yet recruiting - B-cell Lymphoma Clinical Trials

Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma

Start date: September 1, 2021
Phase: Phase 2
Study type: Interventional

Obrutinib is a highly selective BTKi and has shown efficacy in CLL/MCL. This study aims to investigate the initial efficacy and safety of obrutinib combined with R2 regimen in the treatment of relapsed or refractory CD20+B cell lymphoma

NCT ID: NCT05008055 Active, not recruiting - Clinical trials for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

CAPITAL
Start date: November 3, 2021
Phase: Phase 2
Study type: Interventional

This study is an open-label, multicenter Phase II study of capivasertib administered orally in participants with Relapsed or Refractory (R/R) B-cell Non-Hodgkin's Lymphoma (NHL).

NCT ID: NCT05006534 Completed - Refractory Lymphoma Clinical Trials

Polatuzumab Vedotin in Patients With Relapsed and Refractory Diffuse Large B Cell Lymphoma

Start date: June 1, 2020
Phase:
Study type: Observational

This study enrolled patients with relapsed or refractory diffuse large B cell lymphoma treated with polatuzumab vedotin-based chemoimmunotherapies. Patients were allowed to use chemotherapy regimens other than Rituximab and Bendamustine and transplantation following polatuzumab vedotin was also allowed.

NCT ID: NCT05003141 Recruiting - Clinical trials for Mantle Cell Lymphoma

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Start date: November 15, 2021
Phase: Phase 1
Study type: Interventional

Product: PSB202 is a novel biological entity consisting of two engineered monoclonal antibodies, an Fc-enhanced humanized type II anti-CD20 IgG1 (PSB102) and a humanized anti-CD37 IgG1 (PSB107), that target B-cells. PSB202 is manufactured to work as a single product with the two components of PSB202 enabling a distinct dual target-specific antibody directed cell killing of B-cells. Study: Multi-center-, International Phase 1a/1b (Escalation/Expansion) study in patients with indolent-, relapsed-, B-cell malignancies. The Phase 1a (Dose Escalation) part of study follows a 3+3 design.

NCT ID: NCT04995536 Withdrawn - Clinical trials for Recurrent Mantle Cell Lymphoma

CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL

Start date: July 27, 2021
Phase: Phase 1
Study type: Interventional

This phase I trial identifies the best dose and side effects of CpG-STAT3 siRNA CAS3/SS3 (CAS3/SS3) in combination with localized radiation therapy in treating patients with B-cell non-Hodgkin lymphoma that has come back (relapsed) or does not respond to treatment (refractory). CAS3/SS3 simultaneously targets two molecules, TLR9 receptor and STAT3. This investigational drug combines a CpG oligonucleotide and an siRNA in one molecule that act together to interfere with the ability of the cancer cells to grow. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. Giving CAS3/SS3 with localized radiation therapy may kill more cancer cells.

NCT ID: NCT04993690 Recruiting - B-cell Lymphoma Clinical Trials

A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma

Start date: July 6, 2021
Phase: Phase 1
Study type: Interventional

This is an open-label, multi-center Phase 1/2 study of oral LP-168 in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.

NCT ID: NCT04989803 Recruiting - Clinical trials for Relapsed and/or Refractory B-cell Lymphoma

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

Start date: October 27, 2021
Phase: Phase 1
Study type: Interventional

The goal of this clinical study is to learn more about the safety and dosing of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.

NCT ID: NCT04986865 Recruiting - Clinical trials for Advanced Solid Tumor

A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

PROBE
Start date: December 15, 2021
Phase: Phase 1
Study type: Interventional

This is a First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas.

NCT ID: NCT04981795 Recruiting - Clinical trials for Diffuse Large B-cell Lymphoma

realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

realMIND
Start date: September 20, 2021
Phase:
Study type: Observational

The realMIND study is a multicenter, observational study intended to further characterize the safety and effectiveness data of US patients (with a focus on racial and ethnic minority patients) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treated with tafasitamab in combination with lenalidomide.